Liuyan Jiang

1.8k total citations
79 papers, 666 citations indexed

About

Liuyan Jiang is a scholar working on Pathology and Forensic Medicine, Genetics and Neurology. According to data from OpenAlex, Liuyan Jiang has authored 79 papers receiving a total of 666 indexed citations (citations by other indexed papers that have themselves been cited), including 43 papers in Pathology and Forensic Medicine, 26 papers in Genetics and 23 papers in Neurology. Recurrent topics in Liuyan Jiang's work include Lymphoma Diagnosis and Treatment (40 papers), CNS Lymphoma Diagnosis and Treatment (21 papers) and Chronic Lymphocytic Leukemia Research (14 papers). Liuyan Jiang is often cited by papers focused on Lymphoma Diagnosis and Treatment (40 papers), CNS Lymphoma Diagnosis and Treatment (21 papers) and Chronic Lymphocytic Leukemia Research (14 papers). Liuyan Jiang collaborates with scholars based in United States, China and Australia. Liuyan Jiang's co-authors include Wyndham H. Wilson, Elaine S. Jaffe, Han W. Tun, Carlos E. Bueso‐Ramos, James M. Foran, Maryalice Stetler‐Stevenson, Constance M. Yuan, John C. Morris, Rhett P. Ketterling and John E. Janik and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Liuyan Jiang

66 papers receiving 657 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Liuyan Jiang United States 13 379 284 164 123 119 79 666
Marina Narbaitz Argentina 15 423 1.1× 411 1.4× 126 0.8× 113 0.9× 67 0.6× 55 663
Keisuke Kawamoto Japan 14 279 0.7× 245 0.9× 215 1.3× 142 1.2× 43 0.4× 48 646
Alfonso Maria D’Arco Italy 13 358 0.9× 264 0.9× 107 0.7× 248 2.0× 201 1.7× 27 819
Reyes Arranz Spain 14 513 1.4× 373 1.3× 238 1.5× 133 1.1× 178 1.5× 36 757
Alina Nicolae United States 12 394 1.0× 249 0.9× 154 0.9× 107 0.9× 109 0.9× 23 578
Glenn H. Segal United States 17 427 1.1× 266 0.9× 133 0.8× 218 1.8× 80 0.7× 33 739
Eulogio Conde Spain 15 534 1.4× 408 1.4× 177 1.1× 186 1.5× 117 1.0× 43 869
Katalin Kelemen United States 16 220 0.6× 185 0.7× 245 1.5× 154 1.3× 60 0.5× 63 1.1k
Sherif Rezk United States 14 278 0.7× 388 1.4× 132 0.8× 63 0.5× 29 0.2× 41 753
Roberta Burnelli Italy 17 386 1.0× 226 0.8× 113 0.7× 194 1.6× 48 0.4× 40 838

Countries citing papers authored by Liuyan Jiang

Since Specialization
Citations

This map shows the geographic impact of Liuyan Jiang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Liuyan Jiang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Liuyan Jiang more than expected).

Fields of papers citing papers by Liuyan Jiang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Liuyan Jiang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Liuyan Jiang. The network helps show where Liuyan Jiang may publish in the future.

Co-authorship network of co-authors of Liuyan Jiang

This figure shows the co-authorship network connecting the top 25 collaborators of Liuyan Jiang. A scholar is included among the top collaborators of Liuyan Jiang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Liuyan Jiang. Liuyan Jiang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ravindran, Aishwarya, Liuyan Jiang, Gordon Ruan, et al.. (2025). PD-L1 expression and response to immune checkpoint inhibitor therapy in malignant histiocytic neoplasms. Leukemia & lymphoma. 66(14). 2675–2684.
2.
Badar, Talha, Terra L. Lasho, Yael Kusne, et al.. (2024). PPM1D Somatic Mutations in Myeloid Neoplasms: Clinical Profile, Clonal Characteristics and Impact of Concurrent Somatic TP53 Mutations. Blood. 144(Supplement 1). 3218–3218. 1 indexed citations
3.
Ruan, Gordon, Saurabh Zanwar, Aishwarya Ravindran, et al.. (2024). Clinical characteristics, molecular aberrations, treatments, and outcomes of malignant histiocytosis. American Journal of Hematology. 99(5). 871–879. 9 indexed citations
4.
5.
Moustafa, Muhamad Alhaj, Bijan J. Borah, James P. Moriarty, et al.. (2023). Yttrium-90 Ibritumomab Tiuxetan is Cost-Effective Compared to Bendamustine + Rituximab in Low-grade Lymphomas. Clinical Lymphoma Myeloma & Leukemia. 23(4). 259–265. 1 indexed citations
6.
7.
Baidoun, Firas, Bradford S. Hoppe, Jennifer Peterson, et al.. (2023). Clinical characteristics, survival outcomes, and prognostic factors in extranodal natural killer/T-cell lymphoma, nasal type: The National Cancer Database study (2004-2019).. Journal of Clinical Oncology. 41(16_suppl). 7575–7575.
8.
9.
10.
Jiang, Liuyan, et al.. (2022). Primary Bone Marrow Lymphoma: De Novo and Transformed Subtypes. Journal of Blood Medicine. Volume 13. 663–671.
11.
Moustafa, Muhamad Alhaj, Liuyan Jiang, Madiha Iqbal, et al.. (2022). Leukemic High Grade B Cell Lymphoma is Associated With MYC Translocation, Double Hit/Triple Hit Status, Transformation, and CNS Disease Risk: The Mayo Clinic Experience. Clinical Lymphoma Myeloma & Leukemia. 22(8). e815–e825. 2 indexed citations
12.
Iqbal, Madiha, et al.. (2022). Poly‐lymphomatous Syndrome With Concurrent or Sequential Hodgkin and Non‐Hodgkin lymphoma. Clinical Lymphoma Myeloma & Leukemia. 23(2). 138–144. 2 indexed citations
13.
Moustafa, Muhamad Alhaj, et al.. (2021). Primary Cauda Equina Lymphoma Treated with CNS-Centric Approach: A Case Report and Literature Review. Journal of Blood Medicine. Volume 12. 645–652. 5 indexed citations
14.
Seegobin, Karan, et al.. (2021). Macrophage Activation Led Acute Heart Failure Managed Successfully with Immunosuppression. Journal of Blood Medicine. Volume 12. 1037–1043. 3 indexed citations
15.
Moustafa, Muhamad Alhaj, et al.. (2021). Primary age‐related EBV‐associated effusion‐based lymphoma successfully treated with rituximab and thoracentesis. SHILAP Revista de lepidopterología. 9(5). e03971–e03971. 1 indexed citations
16.
Seegobin, Karan, Muhamad Alhaj Moustafa, Liuyan Jiang, & Han W. Tun. (2021). Successful Non-Transplant Treatment of Double Hit Richter Transformation with Long-Term Remission. PubMed. Volume 11. 67–72.
17.
Jiang, Liuyan, Ernesto Ayala, David M. Menke, et al.. (2020). Outcomes of Hepatosplenic T-Cell Lymphoma: The Mayo Clinic Experience. Clinical Lymphoma Myeloma & Leukemia. 21(2). 106–112.e1. 8 indexed citations
18.
Seegobin, Karan, Muhamad Alhaj Moustafa, Mohamed A. Kharfan‐Dabaja, et al.. (2020). Systemic ALK‐positive anaplastic large cell lymphoma with bilateral optic neurolymphomatosis resulting in permanent blindness. SHILAP Revista de lepidopterología. 8(12). 2629–2633. 2 indexed citations
19.
Jiang, Liuyan, et al.. (2013). POEMS syndrome and Castleman disease. Blood. 122(2). 159–159. 8 indexed citations
20.
Jiang, Liuyan, Anaís Malpica, Michael T. Deavers, et al.. (2010). Endometrial Endometrioid Adenocarcinoma of the Uterine Corpus Involving the Cervix: Some Cases Probably Represent Independent Primaries. International Journal of Gynecological Pathology. 29(2). 146–156. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Marina Narbaitz Breakdown of academic impact, for papers by Keisuke Kawamoto Breakdown of academic impact, for papers by Alfonso Maria D’Arco Breakdown of academic impact, for papers by Reyes Arranz Breakdown of academic impact, for papers by Alina Nicolae Breakdown of academic impact, for papers by Glenn H. Segal Breakdown of academic impact, for papers by Eulogio Conde Breakdown of academic impact, for papers by Katalin Kelemen Breakdown of academic impact, for papers by Sherif Rezk Breakdown of academic impact, for papers by Roberta Burnelli
Rankless by CCL
2026